Literature DB >> 8176558

Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease.

S Furukawa1, T Matsubara, Y Umezawa, K Okumura, K Yabuta.   

Abstract

To evaluate the role of tumor necrosis factor alpha (TNF-alpha) during acute Kawasaki disease, we measured p60 soluble tumor necrosis factor receptor (sT-NF-R) shedding into the circulation in 48 patients with acute Kawasaki disease, all of whom received intravenous infusions of gamma-globulin. Of the 48 patients, 5 had coronary artery lesions. Serum concentrations of p60 sTNF-R and TNF-alpha were measured by a sandwich enzyme immunoassay. Patients with Kawasaki disease had increased serum levels of p60 sTNF-R. We found a positive correlation between serum levels of p60 sTNF-R and levels of TNF alpha during acute Kawasaki disease. Moreover, patients with coronary artery lesions had higher levels of sTNF-R than did those without coronary artery lesions. Our findings indicate that p60 sTNF-R levels in serum may be useful for determining the severity of vascular damage during acute Kawasaki disease, and that patients with Kawasaki disease and high sTNF-R levels seem to be susceptible to coronary artery lesions even if they receive therapy with intravenous infusions of gamma-globulin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8176558     DOI: 10.1016/s0022-3476(05)81361-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

1.  Kawasaki disease on PDGF expression and VSMC proliferation.

Authors:  H Wang; H Wang; P Cheng
Journal:  J Tongji Med Univ       Date:  1998

2.  CD14+CD16+ monocyte subpopulation in Kawasaki disease.

Authors:  K Katayama; T Matsubara; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

Review 3.  Immunological profile of peripheral blood lymphocytes and monocytes/macrophages in Kawasaki disease.

Authors:  T Matsubara; T Ichiyama; S Furukawa
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

4.  Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients.

Authors:  Akira Hachiya; Norimoto Kobayashi; Satoshi Matsuzaki; Yusuke Takeuchi; Yohei Akazawa; Tomonari Shigemura; Noriko Motoki; Junya Masumoto; Kazunaga Agematsu
Journal:  Clin Rheumatol       Date:  2018-01-04       Impact factor: 2.980

5.  Anti-inflammatory effect of intravenous immunoglobulin in comparison with dexamethasone in vitro: implication for treatment of Kawasaki disease.

Authors:  Haruyuki Makata; Takashi Ichiyama; Ryutaro Uchi; Tsuyoshi Takekawa; Tomoyo Matsubara; Susumu Furukawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

Review 6.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

7.  Serum resistin concentrations in children with Kawasaki disease.

Authors:  Hiroki Nozue; Hironori Imai; Hisako Saitoh; Takeshi Aoki; Kunio Ichikawa; Tomohiro Kamoda
Journal:  Inflamm Res       Date:  2010-04-27       Impact factor: 4.575

8.  Effects of serum of Kawasaki disease on PDGF expression in monocytes and on endothelial cell apoptosis.

Authors:  H Wang; H Wang; P Cheng
Journal:  J Tongji Med Univ       Date:  1999

Review 9.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

10.  The CCR5 (-2135C/T) polymorphism may be associated with the development of Kawasaki disease in Korean children.

Authors:  Won Kyoung Jhang; Mi-Jin Kang; Hyun-Seung Jin; Jinho Yu; Byoung-ju Kim; Bong Seong Kim; Jong-Keuk Lee; Eul-Ju Seo; Han-Wook Yoo; In Sook Park; Young Mi Hong; Soo-Jong Hong
Journal:  J Clin Immunol       Date:  2008-07-15       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.